Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoSCORE Ⅱ: Sintilimab + Chemotherapy for Resectable Squamous Cell NSCLC
NCT05429463Phase 3Active, not recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in squamous cell carcinoma of the lung (SCCL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Dec 2022; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05429463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429463.